scispace - formally typeset
I

Ian Ganly

Researcher at Memorial Sloan Kettering Cancer Center

Publications -  344
Citations -  21010

Ian Ganly is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Cancer & Thyroid cancer. The author has an hindex of 65, co-authored 301 publications receiving 16531 citations. Previous affiliations of Ian Ganly include Rockefeller University & National Institutes of Health.

Papers
More filters
Journal ArticleDOI

Integrated Genomic Characterization of Papillary Thyroid Carcinoma

Nishant Agrawal, +242 more
- 23 Oct 2014 - 
TL;DR: The genomic landscape of 496 PTCs is described and a reclassification of thyroid cancers into molecular subtypes that better reflect their underlying signaling and differentiation properties is proposed, which has the potential to improve their pathological classification and better inform the management of the disease.
Journal ArticleDOI

Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers

TL;DR: These data support a model of tumorigenesis whereby PDTCs and ATCs arise from well-differentiated tumors through the accumulation of key additional genetic abnormalities, many of which have prognostic and possible therapeutic relevance.
Journal ArticleDOI

The head and neck cancer immune landscape and its immunotherapeutic implications.

TL;DR: HNSCC had the highest median Treg/CD8+ T cell ratio and the highest levels of CD56dim NK cell infiltration, in the authors' pan-cancer analysis of the most immune-infiltrated tumors, and this landscape provides a potentially novel rationale for investigation of agents targeting modulators of Tregs and NK cells in the treatment of advanced HNSCC.
Journal ArticleDOI

Phase II Trial of Intratumoral Administration of ONYX-015, a Replication-Selective Adenovirus, in Patients With Refractory Head and Neck Cancer

TL;DR: ONYX-015 can be safely administered via intratumoral injection to patients with recurrent/refractory SCCHN and evidence of modest antitumoral activity is suggested.